ISLR2: A Potential Drug Target for Autoimmunity, Cancer and Inflammation

Target Name: ISLR2

NCBI ID: G57611

ISLR2

Other Name(s): Leucine-rich repeat domain and immunoglobulin domain-containing axon extension protein | Immunoglobulin superfamily containing leucine-rich repeat 2, transcript variant 1 | ISLR2 variant 1 | immunoglobulin superfamily containing leucine rich repeat 2 | LINX | leucine-rich repeat domain and immunoglobulin domain-containing axon extension protein | KIAA1465 | Immunoglobulin superfamily containing leucine-rich repeat protein 2 | Immunoglobulin superfamily containing leucine rich repeat 2, transcript variant 2 | ISLR2 variant 2 | ISLR2_HUMAN

ISLR2: A Potential Drug Target for Autoimmunity, Cancer and Inflammation

Immunoglobulin (Ig) domain-containing proteins play a crucial role in the immune response against foreign invasion, pathogens, and cancer cells. These proteins are involved in various cellular recognition processes, including antigen, receptor interactions, and intracellular signaling cascades. Leucine-rich repeat (LRR) domain-containing proteins are a subgroup of Ig domain-containing proteins that contain a unique structural feature known as a leucine-rich repeat.

LRR domain-containing proteins have been identified as potential drug targets or biomarkers for various diseases, including autoimmune disorders, cancer, and neurodegenerative diseases. ISLR2, a member of the LRR domain family, has been shown to play a crucial role in multiple biological processes , including inflammation, autoimmunity, and cancer.

ISLR2: Structure and Function

ISLR2 is a 21-kDa protein that contains an N-terminal extracellular domain, a transmembrane region, and a C-terminal LRR domain. The LRR domain is the unique structural feature that gives ISLR2 its name. ISLR2 is expressed in various tissues and cells of the body, including the liver, spleen, muscle, kidney, and central nervous system.

The LRR domain is a conserved structural feature that is found in various proteins that are involved in signaling pathways, including the immune response and inflammation. The LRR domain is composed of a unique array of amino acids that are involved in the formation of a distinct secondary structure, known as a leucine-rich repeat (LRR) dimer.

LRR dimers are a type of protein structure that is composed of two or more independent copies of the same amino acid sequence. The LRR domain is characterized by the presence of a leucine side chain that is rich in polar amino acids, such as lysine, arginine , and glutamic acid. The LRR domain is also known for its ability to form a stable dimeric structure that can interact with other proteins and molecules.

ISLR2 is involved in various biological processes, including inflammation, autoimmunity, and cancer. One of the well-established functions of ISLR2 is its role in the development and progression of autoimmune diseases, such as rheumatoid arthritis, lupus, and multiple sclerosis. ISLR2 has has also been shown to play a crucial role in the regulation of immune cell function, including the activation and proliferation of T cells.

In addition to its role in autoimmunity, ISLR2 is also involved in the regulation of inflammation and cancer. For example, ISLR2 has been shown to play a negative role in the regulation of inflammation and the development of cancer. ISLR2 has also been shown to interact with various proteins involved in the regulation of inflammation and cancer, including nuclear factor kappa B (NF-kappa-B), which is a well-established mediator of inflammation and cancer.

ISLR2 as a Potential Drug Target

The potential use of ISLR2 as a drug target is based on its involvement in various biological processes that are associated with the development and progression of various diseases. ISLR2 has been shown to play a negative role in the regulation of immune cell function and the development of autoimmunity, making it an attractive target for immunosuppressive drugs.

In addition to its potential use as an immunosuppressive drug, ISLR2 has also been shown to be involved in the regulation of inflammation and cancer. ISLR2 has been shown to play a negative role in the regulation of inflammation and the development of cancer, making it an attractive target for anti-inflammatory and anti-cancer drugs.

ISLR2 has also been shown to interact with various proteins involved in the regulation of inflammation and cancer, including NF-kappa-B. This suggests that ISLR2 may be a useful target for drugs that are

Protein Name: Immunoglobulin Superfamily Containing Leucine Rich Repeat 2

Functions: Required for axon extension during neural development

The "ISLR2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ISLR2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets